REAL-WORLD USAGE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH PSORIATIC ARTHRITIS IN GERMANY

被引：0
|
作者：
Song, J. [1 ,2 ]
Anjohrin, S. [3 ]
Abe, C. [4 ]
Banefelt, J. [5 ]
Rieem, Dun A. [5 ]
Picker, N. [6 ]
Kromer, D. [7 ]
Fuchs, A. [8 ]
Hahn, P. [9 ]
Welby, S. [10 ]
机构：
[1] UCB Pharma, Brussels, Belgium
[2] Karolinska Inst, Stockholm, Sweden
[3] UCB Pharma, Brussels, Belgium
[4] Karolinska Inst & Quantify Res, Stockholm, Sweden
[5] Quantify Res, Stockholm, Sweden
[6] Cytel, Wismar, Germany
[7] Cytel, Berlin, Germany
[8] AOK PLUS, Dresden, Germany
[9] Inst Pharmakookonomie & Arzneimittell IPAM, Wismar, Germany
[10] UCB Pharma, Anderlecht, Belgium
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HSD60
引用
收藏
页码：S305 / S305
页数：1
相关论文
共 50 条
  • [31] Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Saito, Shuntaro
    Kondo, Yasushi
    Kaneko, Yuko
    CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1373 - 1378
  • [32] Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers
    Shimada, Hiromi
    Kameda, Tomohiro
    Kanenishi, Kenji
    Miyatake, Nobuyuki
    Nakashima, Shusaku
    Wakiya, Risa
    Kato, Mikiya
    Miyagi, Taichi
    Mansour, Mai Mahmoud Fahmy
    Hata, Toshiyuki
    Kadowaki, Norimitsu
    Dobashi, Hiroaki
    CLINICAL RHEUMATOLOGY, 2019, 38 (05) : 1453 - 1458
  • [33] Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
    Tawaratsumida H.
    Setoguchi T.
    Arishima Y.
    Ohtsubo H.
    Akimoto M.
    Ishidou Y.
    Nagano S.
    Taketomi E.
    Sunahara N.
    Komiya S.
    BMC Research Notes, 10 (1)
  • [34] Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers
    Hiromi Shimada
    Tomohiro Kameda
    Kenji Kanenishi
    Nobuyuki Miyatake
    Shusaku Nakashima
    Risa Wakiya
    Mikiya Kato
    Taichi Miyagi
    Mai Mahmoud Fahmy Mansour
    Toshiyuki Hata
    Norimitsu Kadowaki
    Hiroaki Dobashi
    Clinical Rheumatology, 2019, 38 : 1453 - 1458
  • [35] Healthcare Costs in Psoriatic Arthritis Patients Newly Initiated On a Biologic Disease-Modifying Anti-Rheumatic Drug or Methotrexate.
    Zhang, Frank
    Hiscock, Robert
    Curtis, Jeffrey
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S780 - S780
  • [36] BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PSORIATIC ARTHRITIS: PREDICTORS OF TREATMENT SURVIVAL IN A REAL-LIFE SETTING
    Ceccarelli, F.
    Natalucci, F.
    Olivieri, G.
    Galasso, G.
    Pirone, C.
    Orefice, V.
    Garufi, C.
    Spinelli, F. R.
    Scrivo, R.
    Alessandri, C.
    Conti, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 850 - 850
  • [37] Pharmacogenetics of disease-modifying anti-rheumatic drugs
    Tanaka, E
    Taniguchi, A
    Urano, W
    Yamanaka, H
    Kamatani, N
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (02): : 233 - 247
  • [38] SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS ON THE TREATMENT WITH BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Hasegawa, E.
    Ito, S.
    Kurosawa, Y.
    Taniguchi, S.
    Kobayashi, D.
    Abe, A.
    Otani, H.
    Nakazono, K.
    Murasawa, A.
    Narita, I.
    Ishikawa, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 985 - 985
  • [39] Disease-modifying anti-rheumatic drugs - Cyclosporin
    Chaudhuri, K
    Torley, H
    Madhok, R
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (09): : 1016 - 1021
  • [40] EVALUATION OF ADHERENCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH INFLAMMATORY ARTHRITIS
    Lim, Y. C.
    Teo, W. G.
    Eng, M. N.
    Cheen, H. M.
    Tay, X. Y.
    Yeo, S. I.
    Lim, T. G.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1800 - 1800
12345